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Andrea Sutherland6, Daniel A Salmon3,6 and Jeffrey P Kahn1,4Abstract
Advances in genomics are contributing to the development of more effective, personalized approaches to the
prevention and treatment of infectious diseases. Genetic sequencing technologies are furthering our understanding
of how human and pathogen genomic factors - and their interactions - contribute to individual differences in
immunologic responses to vaccines, infections and drug therapies. Such understanding will influence future policies
and procedures for infectious disease management. With the potential for tailored interventions for particular
individuals, populations or subpopulations, ethical, legal and social implications (ELSIs) may arise for public health
and clinical practice. Potential considerations include balancing health-related benefits and harms between
individuals and the larger community, minimizing threats to individual privacy and autonomy, and ensuring just
distribution of scarce resources. In this Opinion, we consider the potential application of pathogen and host
genomic information to particular viral infections that have large-scale public health consequences but differ in
ELSI-relevant characteristics such as ease of transmission, chronicity, severity, preventability and treatability. We
argue for the importance of anticipating these ELSI issues in advance of new scientific discoveries, and call for the
development of strategies for identifying and exploring ethical questions that should be considered as clinical,
public health and policy decisions are made.Introduction
Genomic information offers the opportunity for more
personalized treatment and prevention [1] in clinical
practice and public health settings. Until recently, such
efforts have focused largely on common, complex disea-
ses (for example, cancers, heart disease, neurodegenerative
diseases) and less common inherited diseases; examples of
such efforts include risk screening, diagnostic sequencing
and pharmacogenomics. Now there is growing interest in
the application of genomics to the management of infec-
tious diseases and epidemics [2], which are among the top
global public health burdens [3]. Rapid and large-scale se-
quencing of pathogen genomes, which provides stronger
and more accurate evidence than was previously possible* Correspondence: ggeller@jhu.edu
1Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD
21205, USA
2Department of Medicine, Johns Hopkins University School of Medicine,
Baltimore, MD 21205, USA
Full list of author information is available at the end of the article
© 2014 Geller et al.; licensee BioMed Central L
12 months following its publication. After this
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.for source and contact tracing, is being applied widely for
disease outbreak management [4] - most recently and
publicly in the case of the Ebola outbreak in West Africa
[5,6]. Additional uses include precise diagnosis of micro-
bial infection, describing transmission patterns, under-
standing the genomics of emerging drug resistance and
identifying targets for new therapeutics and vaccines.
There is growing evidence that, as well as pathogen gen-
etic factors, host genetic factors and the interaction be-
tween host, vector and pathogen influence variability in
infection rates, immune responses [7,8], susceptibility to
infection, disease progression and severity, and response
to preventive or therapeutic interventions [9,10]. As such,
genomic research is improving our understanding of in-
fectious disease pathogenesis and immune response and
may help guide future vaccine development and treatment
strategies [11-18].
While the past few years have seen substantial fed-
eral and private research funding for infectious diseasetd. The licensee has exclusive rights to distribute this article, in any medium, for
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rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Geller et al. Genome Medicine 2014, 6:106 Page 2 of 13
http://genomemedicine.com/content/6/11/106genomics research, there has been little discussion of the
possible ELSIs - for individuals, groups or larger society -
of using genomic information in the management of infec-
tious disease. This gap may be explained in part by the
current paucity of scientific advances in genomics that
have practical applications to infectious disease manage-
ment. Although it may be premature, we must neverthe-
less anticipate the possibility of ELSI-associated challenges
in the future. This Opinion aims to anticipate what some
of these issues might be and under what conditions they
could arise. We argue that these considerations - even as
the science is still developing - should become part of the
agenda of researchers, clinicians, policymakers and public
health officials so that the benefits of genomic applications
to infectious disease are maximized while potential harms
to individuals and populations are minimized.
We begin by acknowledging the existing scholarship
on ELSI issues in the genomics of non-communicable
diseases, and the ethical and legal issues surrounding in-
fectious disease management. Then we briefly describe
some of the epidemiologic characteristics and recent ge-
nomic advances associated with four particular infectious
diseases - Ebola, pandemic influenza, hepatitis B and
tuberculosis - that have large-scale public health con-
sequences but differ in terms of ease of transmission,
chronicity, severity, preventability and treatability, fac-
tors which affect a range of ELSI issues. In this section
we also consider the situations under which the use of
genomic information might or might not be appropri-
ate in the management of infectious diseases. Finally,
we describe some of the major ethical, legal and social
issues that arise in the context of genomics and how
they may play out in the management of these four spe-
cific infectious diseases.
Relevant ethics scholarship: what we know and
what might be ahead?
More than two decades of ELSI research on the appli-
cation of genomics to complex diseases has produced
many insights that are also relevant to infectious disea-
ses [19]. With regard to genetic susceptibility testing in
a clinical setting, issues include the reliability, validity,
confidentiality and disclosure of genetic information. In
the case of clinical next-generation sequencing, and in
genetic cohort studies and biobanks, pertinent issues in-
clude the interpretation of data, data storage, data shar-
ing, informed consent and identifiability/privacy [20-26].
However, a number of factors are unique to infectious
disease, highlighting the importance of investigating whe-
ther novel ELSI issues or variations on existing issues
might emerge from the application of genomics in this
context. Importantly, the nature of disease transmission
differs from that in other types of disease, which has im-
plications for who is at increased risk. Inherited forms ofnon-infectious diseases exhibit vertical transmission -
from one generation to the next. By contrast, infectious
diseases can be transmitted horizontally (in addition to
vertically) to unrelated or unknown individuals, and those
at risk of exposure are often unaware of their risk. In
addition, in the case of infectious diseases, potential bene-
fits or harms of healthcare policy accrue to the entire
population - as in the case of vaccination - in keeping with
the goals of public health. The ethical tensions between
the goals and implementation of personalized medicine
and those of public health, though not new, are high-
lighted by the application of genomics to infectious dis-
ease management.
Existing literature on infectious disease policy, ethics,
and law, outside the context of genomics, describes the
potential for stigmatization of individuals or subpopula-
tions, the challenge of balancing individual interests and
protections (for example, privacy, autonomy, freedom of
movement) against risks of harm to others and to public
health, issues of justice, and employer or health profes-
sional obligations [27,28].
At the intersection of genomics and infectious dis-
eases, there has been some discussion of the ELSIs of
using pathogen genomics for source and contact tracing
[29-31], but little attention has been paid to the ELSI is-
sues regarding testing for and using host genetic infor-
mation in infectious disease prevention and control. As
shown in Figure 1, the introduction of genomic informa-
tion to infectious disease management may complicate
or exacerbate existing ELSI issues, or create variations
on existing challenges for clinical practice, public health
and policy making.
Infectious diseases: epidemiology, characteristics
and recent genomic advances
Infectious diseases account for a significant component
of disease burden worldwide, and are responsible for a
large proportion of morbidity and mortality across all
areas of society [3]. Infectious diseases vary by mode of
transmission (human to human, vector-borne, waterborne,
and so on) and type of pathogen (for example, bacterial,
viral) [2]. Infectious agents can cause acute illness (for in-
stance, influenza) or chronic illness (such as with hepatitis
B virus (HBV) and HIV), and chronic illnesses can some-
times occur with few or no symptoms until the disease
has become significantly advanced.
Strategies for the clinical management and public health
control of different infectious diseases vary depending on
the acuteness and chronicity of infection, infectivity and
virulence of the causative pathogen, modes and ease of
transmission, and whether there are effective treatments,
vaccines, or other means of prevention. These factors,
alone or in combination, are important determinants of
the ELSI issues that may arise with genomic applications
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Figure 1 Status of ELSI issues at the intersection of genomics and infectious diseases. In the near term, the ELSI issues that arise at the
intersection of genomics and infectious disease are likely to reflect new twists on existing ELSI challenges. In the future, as new scientific
discoveries elucidate important host-vector-pathogen interactions, novel ELSI issues might emerge; implications for individuals and society are as
yet unknown and unpredictable.
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transmitted among humans through casual or close con-
tact influences who is at increased risk and whether they
are aware of their risk. Or whether a highly contagious
disease is preventable or treatable may influence the deci-
sion to implement liberty-limiting policies. The genomic
variants associated with infectious diseases may be viewed
as another characteristic that may or may not be useful in
infectious disease management.
When might genomic information be relevant or useful
When safe and effective preventive or therapeutic inter-
ventions exist, it is unwarranted - indeed, unethical - to
use genomic information to stratify patients or the pub-
lic for treatment or disease management; all at-risk or
affected individuals should receive the intervention re-
gardless of genotype. For example, the CCR5Δ32 allele is
associated with resistance to HIV-1 infection and de-
layed AIDS progression in HIV-infected individuals [32].
However, given the effectiveness of antiretroviral thera-
pies [33], treatment would never be withheld from those
who carry the CCR5Δ32 genotype. In the case of the
hepatitis C virus (HCV), IL28B genotype is associated
with response to HCV antiviral treatment and naturalclearance of the virus [34]. Until recently, the available
forms of treatment were not 100% effective and were as-
sociated with burdensome injections and side effects
[35]. At that time, it might have been appropriate to
consider genotyping at-risk individuals and offering
treatment preferentially to those least likely to clear the
virus spontaneously. However, with the development of
combination therapies and other highly effective treat-
ments with few side effects [35], the individual’s ge-
notype is now irrelevant for clinical or public health
decision making. Nevertheless, there are other situa-
tions and diseases for which genomic information might
be useful. We describe below the epidemiology and gen-
omics of four particular infectious diseases - Ebola, pan-
demic influenza, hepatitis B and tuberculosis. We chose
these diseases because of their public health significance
and because, as shown in Table 1, they represent differ-
ent combinations of the characteristics outlined above.
Ebola
The recent Ebola outbreak illustrates the enormous cli-
nical and public health challenges surrounding an infec-
tious, high-mortality disease for which outbreaks are rare
yet potentially devastating. In the past 40 years, Africa has
Table 1 Examples of infectious diseases of varying characteristics, relevant host genomic discoveries and anticipated ELSI issues
Disease example Characteristics Host genetic association(s) Illustrative ELSI issue
Chronicity Contact Severity Treatability Preventability
Ebola Acute Close Unknown; high
case fatality in
epidemics
No No None right now Restricting civil liberties by using
genomic information to inform
quarantine policy or travel restrictions
Fairness implications of genotype-based
triage decisions in resource-limited
settings
Pandemic influenza Acute Casual Variable Yes, but variable Yes, but variable Markers associated with increased
susceptibility to infection, severity
of disease and response to vaccine
Imposing workforce restrictions on
healthcare personnel or selectively
excluding students who are more likely
to be super-spreaders from educational
settings during a pandemic
Hepatitis B Chronic form Close Often Severe Yes, but no cure Yes (vaccine is
95% effective)
Markers associated with vaccine
non-response
Prioritizing access to therapy for vaccine
non-responders based on genotype,











Markers associated with susceptibility
to active disease in particular ethnic
or geographic populations
Targeting specific, marginalized
subgroups for genotyping (for example,
prisoners, native populations, inner city
communities) and then treating
individuals differentially based on their
genetic susceptibility to active infection
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one, which at the time of publication had resulted in more
than 4,800 deaths, is the first epidemic. Because there are
few clinical or laboratory data on people infected with
Ebola, we know very little about the science or epidemi-
ology of the disease. There is currently no approved pre-
vention or treatment other than supportive care. Because
we lack serology data on people in regions of Ebola out-
breaks, it is not known whether there are infected individ-
uals who remain asymptomatic; therefore, the degree of
infectivity of the virus is unknown. We do know that the
risk of transmission is high in the case of direct contact
with bodily fluids of symptomatic individuals (or those
who have died of the illness) and that in an epidemic situ-
ation, where access to adequate health care is poor, the
case fatality rate is extremely high.
Sequencing of the current strain of the Ebola virus has
enabled researchers to trace the outbreak’s origin and
pattern of transmission [5,6]. This technology is currently
the only known genomic application to the understanding
and management of Ebola virus disease. Because people
exposed to Ebola show phenotypic variability in sus-
ceptibility to infection and disease severity, it is likely that
human genetic variation contributes to individual im-
munity and infectivity and that host genetic differences
are one factor among many that interact to influence the
infection.
Hepatitis B
Hepatitis B is found in virtually every region of the
globe. Of the more than 2 billion people who are or have
been infected, 350 to 400 million are carriers of the
chronic disease; the remainder undergo spontaneous re-
covery and production of protective antibodies [36].
Nearly 100% of infected infants (that is, those born to
HBV-infected mothers) become chronically infected.
The risk of developing a chronic infection decreases with
age [37,38].
At least 30% of those with chronic HBV infection ex-
perience significant morbidity or mortality, including cir-
rhosis and hepatocellular carcinoma. Most people do
not know they are infected until they present with symp-
toms of advanced liver disease, which means that in-
fected individuals can spread the infection unknowingly,
sometimes for many years. Although oral antiviral ther-
apies are effective at stopping HBV replication, they do
not cure the disease. Therefore, therapy is usually life-
long. Treatment is also complicated by the development
of drug resistance and side effects. A vaccine against
HBV is safe and effective in 90 to 95% of people; how-
ever, the individuals who are most at risk of becoming
infected are often those with limited access to the vac-
cine, such as marginalized populations or people living
in resource-limited countries.There is substantial evidence that an individual's likeli-
hood of recovering from an acute HBV infection or de-
veloping severe sequelae from infection is influenced, in
part, by genes [39-45]. Candidate gene and genome-wide
association studies have identified variants associated
with HBV-related disease progression or hepatocellular
carcinoma in various populations [46-52]. Treatment
response to interferon (IFN)-α has been associated in
some, but not all, studies with IFNλ3 polymorphisms
[53]. Finally, specific gene variants (HLA and non-HLA
alleles) have been associated with vaccine response and
non-response [54-57].
Pandemic influenza
Acute viral infections such as influenza also have pro-
found impacts on global health [58]. In contrast to the
yearly epidemics caused by seasonal influenza, a pan-
demic can occur when a new virus emerges in a naive
population and is readily transmitted from person to
person [59]. The US Centers for Disease Control (CDC)
estimates that the H1N1 2009 pandemic resulted in 41
to 84 million infections, 183,000 to 378,000 hospitali-
zations, and nearly 285,000 deaths worldwide [60]. Al-
though the morbidity and mortality of that pandemic
were lower than feared, public health professionals con-
tinuously monitor for the emergence of more virulent
strains [61].
As an airborne infection, influenza is transmitted easily
and quickly, and its effects can be acute, although there is
wide variability in response to infection. Much of the het-
erogeneity in the severity of seasonal influenza infections
has been attributed to the degree of acquired immunity in
the population affected, patient co-morbidities and the
virulence of the strain. Also, influenza epidemics and
pandemics are often caused by the introduction of novel
viruses for which most people have limited acquired im-
munity. The emergence of new strains, and the lack of
cross-protection by existing vaccines, does not leave
much time for vaccine development. In pandemics, in-
cluding the H1N1 2009 influenza pandemic, healthy
young individuals with no co-morbidities have comprised
a significant proportion of fatal and severe cases [62].
These pandemics have provided an opportunity to evalu-
ate the host innate immune response among populations
without underlying background immunity.
Research has identified genetic factors associated with
severity of illness due to influenza [63-65] and death
from severe influenza [66]. Genetic information about
immune response to influenza could inform vaccine de-
velopment and distribution, and disease treatment strat-
egies [17,67,68]. Several candidate gene studies suggest
that variations in HLA class 1 and other genes contrib-
ute to differences in antibody response to influenza vac-
cines [15,69,70]. Ongoing experience with vaccine use
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role of genetics in vaccine safety and efficacy [71,72].
Tuberculosis
Tuberculosis causes 1.5 to 2 million deaths per year
worldwide, second only to HIV in mortality due to an
infectious disease. It is estimated that one-third of the
global population has latent tuberculosis. Those in-
fected have about a 10% lifetime risk of becoming ill
with active tuberculosis; however, this risk is much
higher for people whose immune system is compro-
mised by HIV infection, malnutrition or other illness.
Only the active form of tuberculosis is contagious but
it is easily transmitted through casual contact. Tubercu-
losis occurs all over the world, but 95% of tuberculosis-
related deaths occur in low- and middle-income countries
[73]. The disease is only minimally preventable; the vac-
cine that is used in areas of high endemicity is about
20% effective [74]. Active tuberculosis is treatable (and
curable), but disease control and treatment adherence
are complicated by a variety of factors, including avail-
ability of healthcare resources, multidrug-resistant tu-
berculosis strains and potentially toxic side effects of
treatment.
Gene variation has been associated with susceptibility
to active tuberculosis in specific populations. For ex-
ample, a particular gene variant in the promoter region
of the IL10 gene is associated with a 40 to 60% increased
risk of developing active tuberculosis among Europeans
and Americans [75]. Further research on host genomics
is likely to identify genetic contributions to the pheno-
typic variability seen in tuberculosis infection, and lead
to improvements in the efficacy of preventive and the-
rapeutic interventions. Moreover, sequencing of the pa-
thogen is being used to describe tuberculosis outbreak
dynamics when traditional contact tracing cannot iden-
tify the source [76].
Other infectious diseases and recent genomic advances
In addition to diseases that are transmitted from human
to human by air, blood or other bodily fluids, there are
entire classes of globally burdensome infectious diseases
that have different modes of transmission but exhibit
similar variability in degrees of preventability, infectivity,
transmission risk, treatability and chronicity.
Waterborne diseases, such as cholera, are a significant
global public health burden and are among the most im-
portant causes of illness in areas with poor sanitation [77].
Recent genomic advances are contributing to our under-
standing of the emergence and spread of a multidrug-
resistant cholera strain [78], for example, and helping to
identify variants that might account for differences in
host susceptibility to other waterborne infections such
as schistosomiasis [79,80].Vector-borne diseases, including malaria and dengue,
are among the most common infectious diseases around
the globe. Recent studies have identified genetic variants
that account for variability in human susceptibility and
severity of infection and might be useful for vaccine and
treatment development in malaria [80-84] and dengue
[85,86], for example.
Nosocomial infections, such as methicillin-resistant
Staphylococcus aureus (MRSA), pose a major challenge
to clinical management and health policy [87]. Recent
whole-genome sequencing (WGS) of MRSA clones made
it possible to trace the origin, evolution and global spread
of EMRSA-15, currently the most rapidly spreading and
tenacious healthcare-associated clone in Europe [88].
These are just a few examples of other types of infec-
tious diseases for which genomic advances may play a
role in prevention and control, with corresponding ELSI
issues.
ELSI challenges in genomics and infectious
disease
The ELSI issues associated with at least one application
of genomics to infectious disease management have re-
ceived some attention. The ability to identify a human
source of infection or a ‘super-spreader’ creates potential
questions of blame or legal liability, stigmatization, and
risks to privacy [29,30]. Similar issues could arise from
the ability to identify people at a higher risk for contract-
ing or spreading a disease using human genetic markers.
Below we explore some of the key ethical and social con-
siderations, as well as legal and policy considerations,
that are relevant to host genomic discoveries, followed
by particular examples of ELSI issues that may arise if
we apply genomic discoveries to four specific infectious
diseases that differ in a number of ELSI-relevant charac-
teristics (Table 1).
General ethical and social considerations
In the context of any technological advances in biomed-
ical science, ethical challenges often arise when there is
a lag time between the ability to identify a problem and
the capacity to address it. In the case of infectious dis-
eases, we may be able to identify those at increased risk
of contracting or transmitting infection, or those more
or less likely to respond to interventions, before we have
safe and effective interventions to offer, or before policy
can be modified. Another major ethical challenge results
from the variability in the predictive value of genotypic
information and how such information can be used to
inform risk management policy when our understanding
of risk is inexact. The significance of genomic informa-
tion, and the uses to which it is put, may give rise to the
following specific ELSI-related concerns: (1) an imbal-
ance in health-related benefits and harms to individuals
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sonal information, autonomy, choice and limitations on
liberty; (3) the social and behavioral impact of genomic
information on individuals, family members and others;
and (4) the equitable distribution of scarce resources. Al-
though these issues are not unique to infectious diseases,
they need to be considered as our scientific understand-
ing of the role of genomics in infectious disease manage-
ment advances. What may be unique at the intersection
of genomics and infectious disease control are ethical
challenges that stem from the inherent tension between
the goals of personalized medicine, which are to benefit
particular individuals, and those of public health - to
benefit and protect entire populations.
Benefits and harms to individuals and populations
The potential for risk, as well as benefit, is inherent in
scientific discovery. One of the ethical justifications for
incorporating biomedical advances in clinical practice
and public health is that the benefits to individuals and/
or populations outweigh the potential harms. Moreover,
specific subgroups of the population should not dispro-
portionately reap the benefits or shoulder the burdens of
harm. Genomic discoveries related to infectious disease
have the potential to benefit at-risk and affected individ-
uals, and minimize harm to them, by identifying more
effective preventive or therapeutic interventions and cla-
rifying whether a pathogen or the treatment accounts
for an adverse reaction to an intervention. An interven-
tion would be ethically justified if the likelihood of an ef-
fective immune response significantly outweighs the risk
and severity of adverse reactions to the intervention. It
has been suggested that targeting therapeutic interven-
tions to those more likely to develop severe illness and
then protecting them from adverse reactions could be
useful in pandemic planning [89]. In the context of pre-
vention, genomic discoveries could also be used to mi-
nimize vaccine-associated adverse events, and augment
immune responses in individuals who would otherwise
have low or no response to vaccination [7].
Cost-benefit analyses and overall predicted impact on
morbidity and mortality might also influence the ethical
justifiability of preventive interventions. With the ability
to identify a genetic predisposition for adverse events
following vaccination, immunization programs might de-
cide to screen for this genetic risk factor. For example, a
recent discovery points to a gene variant associated with
a significantly increased risk of febrile seizure following
vaccination for measles, mumps and rubella (the MMR
vaccine) [90]. Febrile seizures are rare and usually be-
nign, raising questions about whether children should be
routinely screened for such markers prior to vaccination.
If so, and parents are informed of the results, they might
decline to vaccinate children who are at increased risk ofadverse side effects, risking infection for their children
and undermining herd immunity for others. In light of
the tremendous public funding and strong support for
vaccines from state and federal authorities, it is not clear
whether immunization programs have a moral obligation
to screen for genetic risk factors, even if screening is not
cost-effective.
Privacy, autonomy and choice
In the United States, clinical decision making has long
been tailored to the characteristics, needs and wishes of
the individual patient. Along with a physician's obliga-
tion to base treatment decisions first and foremost on
the wellbeing of the patient come additional responsibil-
ities to respect the patient’s autonomy and privacy. In
the context of infectious disease management, individual
rights and liberties such as autonomous decision mak-
ing, freedom of choice and action, privacy, and the right
to know or not to know information about oneself can
come into conflict with public health priorities. Whereas
public health programs may already target people or
subgroups with particular risk factors, the possibility of
ascertaining (or requiring reporting of) otherwise unob-
servable genetic risk factors may complicate issues of pro-
tection of personal information, privacy and autonomy.
Considerations of privacy and autonomy are being chal-
lenged on a massive scale by WGS and whole-exome
sequencing (WES), technologies that are expected to
contribute to our understanding of host genomics in
the context of infectious disease. The planned, as well
as unforeseen, uses of the genomic data generated by
WGS and WES about individuals and populations raise
a range of ethical issues both for initial sequencing and
for subsequent use of the data [20-22]. The growing lit-
erature on the ethical implications of WGS and WES
has so far focused on privacy concerns, data sharing
[23], return of results, the management of incidental
findings [24] and best practices for obtaining informed
consent, at least in the context of research [25,26]. The
development and implementation of informed consent
policies and practices for the public health uses of
WGS information will need to consider (1) whether the
information that people ought to have in the context of
infectious disease prevention, control and management
is different in ethically relevant ways from what is pro-
vided in the context of other diseases and behavioral
traits, and (2) whether the processes for disclosing infor-
mation about host genomics should vary, for example, in
different parts of the world.
We cannot predict how genetic information might be
used in the context of public health or policy decisions;
indeed, establishing thresholds for utility in the public
health context is made difficult by the probabilistic na-
ture of genomic information. However, we believe it is
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ing could be used (or mandated) and how its use could
affect personal liberties. Genomic data about individuals
(their genomic ‘fingerprint’) might be consulted when
decisions about prevention and treatment are consid-
ered; for example, which vaccine formulation is appro-
priate, which drugs are likely to be most effective, and
what dosage over what period of time. Genomic data
about individuals and groups might be consulted during
disease outbreaks, in planning for public health pro-
grams, or in developing new or assessing existing public
health policies; for instance, where are the hotspots for
infection (and are these associated with specific patho-
gen or host genomics), where should vaccines be de-
ployed most urgently, which therapies should be offered
to which genomic populations, and where should treat-
ment programs, isolation policies or public health control
programs be implemented to halt the spread of infections?
Genetic markers of infectivity or likelihood of being a
super-spreader could be used to justify quarantine and
isolation policies, with the concomitant implications for
individual liberty. The value placed on individual auto-
nomy varies in different cultures, so the primacy that it
receives in the context of public health planning and deci-
sion making, and the role of informed consent, might dif-
fer between countries [91,92].
Social and behavioral impact of genomic information
A number of infectious diseases are transmitted through
behaviors that are stigmatizing. Viruses such as HBV,
HCV and HIV are commonly transmitted through injec-
tion drug use and high-risk sexual practices. Genomic
information that can predict the risk of susceptibility to,
or transmission of, disease might influence the actual
behaviors of individuals in these at-risk groups. For
example, the knowledge that a particular genotype de-
creases the risk for developing chronic hepatitis C
might lead to an increase in risk-taking behavior. An
overestimate of the predictive value of genetic infor-
mation emanates from genetic essentialism, the belief
that genes are wholly predictive of diseases, behaviors,
or traits [93]. The assumption that outcomes are more
attributable to genes than is accurate underestimates
the importance of individual behavior and contributes
to a false sense of security.
In addition to influencing the actual behavior of high-
risk individuals, genetic information could affect atti-
tudes and beliefs about the individuals who engage in
risky behavior. The knowledge that a genetic variant
increases the risk of spreading a sexually transmitted
disease might lead to negative judgments about, and
marginalization of, individuals who carry that variant.
Discrimination against entire subgroups could also occur
if, for example, genetic variants were found to correlatewith a more favorable vaccine or treatment response, but
only in certain ethnic groups; also, drug development
might focus on these ‘more responsive’ subgroups.
Allocation of scarce resources
Disparities in access to critical resources, including pre-
ventive or therapeutic drugs, can be due to financial,
educational, sociocultural, geographical or environmen-
tal barriers. When circumstances, such as a pandemic,
create a demand for resources that is greater than the
supply, decisions must be made about how to distribute
the resources. In the face of shortage, or differential ac-
cess, genetic information could be used to make triage
decisions or decide who receives a vaccine or therapy.
Biomedical research funding decisions could be influ-
enced by the availability of specific genetic information.
Special vaccine formulations might be developed and
produced for at-risk genetic (‘orphan’) subgroups. It re-
mains to be seen what the implications would be for
health insurance coverage and public financing of treat-
ments if vaccines or treatments vary by genotype. The
extent to which infectious disease genomics will be
translated into benefits for individuals or public health is
dependent largely on the allocation of resources for re-
search and development efforts. The majority of research
investment comes from high-income countries, whereas
the highest burden of infectious disease is in the deve-
loping world. The kind of research likely to have the
greatest global benefits might not be given funding prior-
ity by countries with the greatest resources. Differences in
regional investments in genomic science and technology
will have important implications for the equitable distribu-
tion of benefits and public health impact [94].
Legal and policy considerations
The legal and policy paradigm in genomics - which places
a high value on privacy - can conflict with the public
health framework, in which individual rights can be over-
ridden for the benefit of others [95]. All US states have
enacted genetic privacy legislation, but the scope of the
protections afforded by these laws varies from state to
state. The extent to which genetic privacy provisions in
these statutes may conflict with state public health laws is
unclear. The Model State Emergency Health Powers Act
enumerates the powers that will be granted to state and
local officials to protect public safety in the event of a pub-
lic health emergency, and includes provisions related to
mandatory vaccination and quarantine [96]. Many states
have adopted at least some of the provisions of the model
legislation [97].
Host genomic factors could be important in determin-
ing: (1) which individuals should be vaccinated in the case
of a public health emergency - those who are at highest
risk for severe disease; (2) which individuals should not be
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following vaccination; or (3) which individuals should be
quarantined, because of increased risk to themselves or to
others. It is unclear whether state emergency powers
would override genetic privacy protections in these cir-
cumstances, and it is possible that, under current laws,
genetic privacy provisions would prevail in circumstances
in which a disease outbreak does not rise to the level of a
public health emergency.
Similarly, the US federal Genetic Information Non-
discrimination Act of 2008 (GINA) [98] forbids discrim-
ination on the basis of genetic information in any aspect
of employment, including job placement. Some individ-
uals may be better suited than others to work in high-risk
job placements during an infectious disease outbreak be-
cause they are more likely to have an adequate response
to a vaccine, or because their genotype is associated with a
lower risk of developing severe infection. Alternatively,
some individuals might have a variant associated with in-
creased risk of severe infection. In both situations, the
provisions of GINA may limit the ability to use genetic in-
formation to determine which employees would be most
appropriate for high-risk job placements in case of an in-
fectious disease outbreak.
Host genomic factors may have additional legal and
policy implications. For example, providers may face in-
creased liability for vaccine-related injury in patients
whose genotype is associated with greater risk of adverse
events following vaccination. Alternatively, those who
are found to be at increased risk for adverse events might
be exempted from mandatory vaccine laws, potentially af-
fecting herd immunity.
As our knowledge of the role of pathogen and host
genomic factors in the prevention and treatment of in-
fectious disease expands, it is critical that we evaluate
current legal frameworks to determine the extent to which
current genetic privacy laws - for example, both state and
federal in the US - may hinder our ability to use genetic
information to protect the health of both individuals and
the general public. Privacy laws are likely to vary in differ-
ent countries, and international frameworks for protecting
privacy in the context of genomics and infectious diseases
will also need to be evaluated.
Illustrative ELSI issues in genomic applications for
particular infectious diseases
Ebola
The potential severity of Ebola virus disease, coupled
with the absence of effective prevention or treatment,
generates interest in determining whether there are host
factors that protect people from, or increase their sus-
ceptibility to, contracting or spreading the infection. At
present, the science of host genomics and pathogen-host
interaction is not well understood and, arguably, is notas important as developing treatments. However, im-
agine if we could identify genetic variants that are asso-
ciated with an increased likelihood of contracting Ebola,
spreading it, having more severe disease or responding
to treatment. An ethical tension would arise if we were
to consider screening at-risk populations for such vari-
ants and using the genomic information to influence a
range of clinical and public health decisions. For exam-
ple, in the absence of effective interventions and suf-
ficient facilities to treat everyone, genetic information
might be used to triage patients at greatest risk of severe
disease to receive care first. Or we might impose travel
restrictions or quarantine only on those who are at grea-
ter risk of contracting or spreading the virus. These and
other ethical, legal and social challenges need to be con-
sidered when designing and conducting genomic research
on host factors and host-vector-pathogen interactions in
Ebola virus disease.
Influenza
Since the transmission of influenza virus does not re-
quire close contact, influenza is easier to contract than
Ebola and HBV. In the case of pandemic influenza, the
severity of the disease and the efficacy of vaccines and
treatments are variable, suggesting that limiting exposure
is a more promising strategy than relying on interven-
tions. Markers associated with increased susceptibility
to infection, severity of disease and response to vaccine
could be used to influence workforce decisions. For ex-
ample, greater responsibilities might be assigned to health-
care workers with genotypes that predict higher resistance
to influenza, a greater chance of mild infection, or positive
response to the vaccine. Genotyping of healthcare workers
might be used, or even required, to determine who can be,
or possibly who must be, first responders and, by contrast,
who must stay at home. Children might also be screened
so as to exclude super-spreaders from going to school. In
both of these cases, a higher value would be placed on re-
ducing risk to patients or classmates than on the privacy
and autonomy of employees or students, respectively.
Hepatitis B
Unlike Ebola, HBV is both treatable and preventable. Al-
though the preventive vaccine is highly effective, 5% of
individuals do not respond, and genetic predictors of
vaccine non-response are being identified [99]. Screening
for such genetic markers could exempt non-responders
from vaccination that would otherwise be mandatory,
for instance among healthcare workers. Such screening
could also influence decisions about access to therapy,
especially in settings with limited resources. Treatment
for hepatitis B, although very effective, is not curative. If
an immunotherapy-based cure is found, treatment might
be provided preferentially to individuals with genotypes
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sources for such therapies are scarce. Also, individuals
with genotypes associated with better response to im-
munotherapy may receive priority for treatment. Alter-
natively, those most likely to die from these infections
might be given priority if vaccines are scarce.
Tuberculosis
Like influenza, tuberculosis is airborne and can be trans-
mitted through casual contact. Unlike the diseases de-
scribed above, tuberculosis can be latent. Although people
with latent tuberculosis cannot spread the disease, the
ability to test for increased genetic susceptibility to de-
velopment of active disease could lead to unfair treatment
of specific subpopulations that are already marginalized,
and could allow familiar ethical issues surrounding the
justifiability of ethnic stratification to surface [100-103].
The prevalence of tuberculosis is highest among those in
resource-limited settings and crowded environments such
as prisons and inner cities. These subgroups could be
targeted to undergo testing for susceptibility to active
disease, and then treated differentially based on their
genotype.
In addition, tuberculosis provides one example in which
pathogen and host genomics can be used in combination
to identify those at increased risk and to implement mea-
sures to control the spread of disease. Sequencing the
pathogen can identify the individual who is the source
of an outbreak. Those infected by that individual could
be pressured to undergo genetic testing and to agree to
regular follow-up if they are at increased risk of active
infection.
Conclusions and future directions
We anticipate that genomic discoveries will improve our
understanding of infectious disease and inform new stra-
tegies for management. Future research directions will
shed light on the additional importance of host-pathogen-
vector interactions and environmental influences. For
example, research on the microbiome - the collective
genomes of the microorganisms that inhabit our bodies -
is yielding increasing evidence for its role in infectious
disease [104,105].
Drawing on four paradigmatic infectious diseases, we
have attempted to sketch a view of what the future may
hold in terms of ELSI considerations at the intersec-
tion of genomics and infectious disease. Some important
challenges relate to balancing health-related benefits and
harms between individuals and the larger community,
minimizing threats to individual liberties, and promoting
justice in the distribution of scarce resources and the
treatment of marginalized subgroups. While it is too
early to identify all of the potential ELSI issues that
may emerge in this field, such considerations should befactored into the development of policy recommenda-
tions for public health and clinical practice in infectious
disease, both domestically and internationally [106]. At-
tention to ELSI issues could also guide research ques-
tions and decisions about public funding of science.
This would contribute to the ongoing systematic effort
to provide an evidence base for the utility and priority
of genomic applications in public health [107,108].
A number of frameworks have been developed for
identifying and responding to important issues in the
prevention and control of infectious disease [109-111].
An important next step is to develop a framework for
spotting and elucidating ELSI issues pertinent to infec-
tious disease genomics that considers the disease charac-
teristics discussed above. We do not have the luxury of
waiting until the science matures to consider the poten-
tial consequences of these advances. Instead, we must
work to predict ELSI issues and be ready to address
them as they arise in order to ensure just and sustain-
able solutions that minimize harm and maximize bene-
fits [112].
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